Twin Capital Management Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 3.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,490 shares of the biotechnology company’s stock after buying an additional 1,150 shares during the period. Twin Capital Management Inc.’s holdings in United Therapeutics were worth $4,659,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in UTHR. First Allied Advisory Services Inc. grew its position in shares of United Therapeutics by 0.4% during the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 19 shares in the last quarter. Guardian Capital LP grew its position in shares of United Therapeutics by 5.9% during the 2nd quarter. Guardian Capital LP now owns 2,623 shares of the biotechnology company’s stock valued at $340,000 after purchasing an additional 145 shares in the last quarter. M&T Bank Corp grew its position in shares of United Therapeutics by 8.8% during the 2nd quarter. M&T Bank Corp now owns 2,217 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 179 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of United Therapeutics by 8.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,272 shares of the biotechnology company’s stock valued at $296,000 after purchasing an additional 180 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in shares of United Therapeutics by 1.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,485 shares of the biotechnology company’s stock valued at $1,749,000 after purchasing an additional 231 shares in the last quarter.

Shares of United Therapeutics Co. (UTHR) opened at $138.37 on Tuesday. United Therapeutics Co. has a fifty-two week low of $112.01 and a fifty-two week high of $169.89. The stock has a market cap of $5,980.00, a price-to-earnings ratio of 12.20 and a beta of 1.41.

A number of research firms have recently commented on UTHR. Wedbush restated an “outperform” rating and set a $232.00 price target (up from $213.00) on shares of United Therapeutics in a research report on Wednesday, December 27th. ValuEngine upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 30th. BidaskClub upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b” rating in a research report on Friday, December 15th. Finally, Oppenheimer boosted their price target on shares of United Therapeutics to $180.00 and gave the company an “outperform” rating in a research report on Friday, January 5th. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $140.27.

In other news, CEO Martine A. Rothblatt sold 1,269 shares of United Therapeutics stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $118.04, for a total transaction of $149,792.76. Following the completion of the sale, the chief executive officer now directly owns 1,409 shares of the company’s stock, valued at approximately $166,318.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 7,061 shares of United Therapeutics stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $121.12, for a total transaction of $855,228.32. The disclosure for this sale can be found here. Insiders have sold a total of 13,245 shares of company stock valued at $1,622,581 over the last ninety days. 7.80% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Twin Capital Management Inc. Acquires 1,150 Shares of United Therapeutics Co. (UTHR)” was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.watchlistnews.com/twin-capital-management-inc-acquires-1150-shares-of-united-therapeutics-co-uthr/1832463.html.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.